{rfName}
Ex

Indexed in

License and use

Citations

1

Altmetrics

Grant support

Projects PIE15/00068, PI17/01865 and PI20/01458 (Instituto de Salud Carlos III) awarded to RC; Projects FIS PI19/01491 and CIBER Cardiovascular (Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III with co-funding from the Fondo Europeo de Desarrollo Regional FEDER) awarded to AA; CNIO Bioinformatics Unit is supported by the Instituto de Salud Carlos III (ISCIII); Project RETOS RTI2018-097596-B-I00 (AEI/10.13039/501100011033 MCI/FEDER, UE); Projects PI17/00801 and PI21/01111 grants from Instituto de Salud Carlos III and JR17/00007 awarded to NRL, and Project Molecular analysis of the Exhaled Breath Condensate in the management of solitary pulmonary nodule (ideas semilla AECC 2019), from Asociacion Espanola Contra el Cancer (AECC) awarded to JA.

Analysis of institutional authors

Romero-Laorden, NAuthorMondejar, RAuthorAspa, JAuthorAlfranca, AAuthorColomer, RAuthor

Share

Publications
>
Article

Excess weight and anti-PD-1 immune checkpoint inhibitor’s outcomes in non-small cell lung cancer

Publicated to:Clinical & Translational Oncology. 24 (11): 2241-2249 - 2022-11-01 24(11), DOI: 10.1007/s12094-022-02887-8

Authors: Rogado, Jacobo; Pozo, Fernando; Troule, Kevin; Sanchez-Torres, Jose Miguel; Romero-Laorden, Nuria; Mondejar, Rebeca; Donnay, Olga; Ballesteros, Anabel; Pacheco-Barcia, Vilma; Aspa, Javier; Al-Shahrour, Fatima; Alfranca, Arantzazu; Colomer, Ramon

Affiliations

Hosp Cent Defensa Gomez Ulla, Med Oncol Dept, Madrid, Spain - Author
Hosp Univ Infanta Leonor, Med Oncol Dept, Gran Via Este 80, Madrid 28031, Spain - Author
Hosp Univ Princesa, Immunol Dept, Madrid, Spain - Author
Hosp Univ Princesa, Inst Invest Sanit, Madrid, Spain - Author
Hosp Univ Princesa, Med Oncol Dept, Madrid, Spain - Author
Hosp Univ Princesa, Neumol Dept, Madrid, Spain - Author
Spanish Natl Canc Res Ctr, Bioinformat Unit, Madrid, Spain - Author
Univ Autonoma Madrid, Chair Personalized Precis Med, Madrid, Spain - Author
Univ Autonoma Madrid, Dept Med, Madrid, Spain - Author
See more

Abstract

Purpose Immune checkpoint inhibitors are one of the most effective treatments available in advanced non-small cell lung cancer. However, at present, there are no clinical or analytical biomarkers that define which patients benefit with certainty from these treatments. In our study, we evaluated whether excess weight could be a good predictive biomarker of benefit from these drugs. Methods We studied a population of 79 patients, divided into a study group with 39 patients diagnosed with non-small cell lung cancer treated with immunotherapy and 40 patients in a control group, diagnosed with different advanced cancers, treated with non-immunotherapy treatment. We analyzed according to the presence of excess weight or not, the treatment's outcome in the study group and in the control group (objective response, and progression-free and overall survival). Results In our study, we detected a better response rate to immunotherapy in patients with excess weight (62.50 vs 26.08%, OR 4.72, p = 0.02), and a better median progression-free survival (14.19 vs 5.03 months, HR 0.50, p = 0.058) and median overall survival (33.84 months vs 20.76 months, HR 0.43, p = 0.01) in the study group. These findings were specific to the immunotherapy group since in the control group, with patients who did not receive immune checkpoint inhibitors, these findings were not found. Conclusion Our study suggests that patients with excess weight who receive anti-PD-1 immune checkpoint inhibitors diagnosed with non-small cell lung cancer have a better outcome. This effect is specific to patients receiving immunotherapy.

Keywords

excess weightimmune checkpoint inhibitorsimmunotherapynon-small cell lung cancerAssociationBody-mass indexClinical-outcomesExcess weightImmune checkpoint inhibitorsImmunotherapyMortalityNon-small cell lung cancerObesityOutcome predictorsOverweight

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical & Translational Oncology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine (Miscellaneous). Notably, the journal is positioned en el Cuartil Q3 for the agency WoS (JCR) in the category Oncology.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-06-15:

  • Scopus: 1
  • OpenCitations: 4

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-15:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 13.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 13 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.25.
  • The number of mentions on the social network X (formerly Twitter): 2 (Altmetric).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (COLOMER BOSCH, RAMON).